ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) VP Meredith Cook sold 500 shares of the firm’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $81.84, for a total transaction of $40,920.00. Following the sale, the vice president owned 77,390 shares of the company’s stock, valued at approximately $6,333,597.60. This represents a 0.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Meredith Cook also recently made the following trade(s):
- On Friday, June 12th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $82.03, for a total transaction of $41,015.00.
- On Wednesday, May 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $78.16, for a total transaction of $39,080.00.
ANI Pharmaceuticals Stock Up 1.4%
ANI Pharmaceuticals stock opened at $81.92 on Friday. The stock has a market cap of $1.86 billion, a P/E ratio of 20.74 and a beta of 0.43. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. ANI Pharmaceuticals, Inc. has a twelve month low of $62.60 and a twelve month high of $99.50. The company’s 50-day moving average price is $81.43 and its two-hundred day moving average price is $79.51.
Institutional Investors Weigh In On ANI Pharmaceuticals
Large investors have recently added to or reduced their stakes in the stock. Maryland State Retirement & Pension System increased its stake in ANI Pharmaceuticals by 5.4% during the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after acquiring an additional 134 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of ANI Pharmaceuticals by 1.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after acquiring an additional 143 shares during the period. CANADA LIFE ASSURANCE Co lifted its position in shares of ANI Pharmaceuticals by 1.0% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after acquiring an additional 198 shares during the period. Oregon Public Employees Retirement Fund grew its holdings in shares of ANI Pharmaceuticals by 5.1% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock worth $323,000 after purchasing an additional 200 shares in the last quarter. Finally, Federation des caisses Desjardins du Quebec grew its holdings in shares of ANI Pharmaceuticals by 0.6% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock worth $3,110,000 after purchasing an additional 221 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.
Analysts Set New Price Targets
Several research firms recently issued reports on ANIP. Guggenheim restated a “buy” rating and issued a $124.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Canaccord Genuity Group set a $91.00 target price on shares of ANI Pharmaceuticals in a research report on Thursday. Finally, Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $105.00.
View Our Latest Stock Report on ANIP
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Featured Articles
- Five stocks we like better than ANI Pharmaceuticals
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
